Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells
2018 ◽
Vol 17
(2)
◽
pp. 499-507
◽
Keyword(s):
2019 ◽
Keyword(s):
2019 ◽
Keyword(s):
2010 ◽
Keyword(s):
Keyword(s):
2017 ◽
Vol 43
(1)
◽
pp. 29-37
◽
Keyword(s):
Keyword(s):
2014 ◽
Vol 106
(9)
◽
Keyword(s):
Keyword(s):
Keyword(s):